Similarly, the NRG-LU004 trial assesses the combination of durvalumab concomitantly with RT followed by durvalumab for 1 year in patients with PD-L1 ⩾50% NSCLC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.